|Bid||52.10 x 1300|
|Ask||0.00 x 900|
|Day's Range||55.30 - 57.15|
|52 Week Range||48.14 - 75.75|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||23.56|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||1.91 (3.44%)|
|1y Target Est||55.93|
Based on Cardinal Health Inc’s (NYSE:CAH) earnings update on 30 September 2018, analysts seem highly optimistic, with earnings expected to grow by a high double-digit of 83% in the upcoming Read More...
Cardinal Health Inc. is putting federal tax savings and proceeds of a partial divestiture into more share buybacks and capital investments, while continuing cost-cutting measures.
The CAH chart, below, shows the stock price had been in a consistent downtrend from January of this year, making a series of lower lows and lower highs. The market selloff in October resulted in CAH successfully testing its $50.00 support level. Given that CAH had previously violated its downtrend, based for approximately six months and has now violated long-standing resistance with respectable volume, we believe it has formed a bullish reversal pattern.
Cardinal Health posted a more than fivefold surge in first-quarter profit, led by growth in its pharmaceuticals business despite generic drug competition pressures.
Shares of Cardinal Health Inc. rallied 2.9% in premarket trade Thursday after the healthcare services company reported fiscal first-quarter profit and revenue that rose above expectations, boosted by strength in its pharmaceuticals business. Net income rose to $593 million, or $1.94 a share, from $115 million, or 36 cents a share, in the same period a year ago, with the naviHealth divestiture resulting in a gain of $503 million. Excluding non-recurring items, adjusted earnings per share came to $1.29, above the FactSet consensus of $1.08. Revenue increased 8% to $35.2 billion, beating the FactSet consensus of $33.7 billion. Pharmaceutical segment revenue grew 9% to $31.4 billion, well above the FactSet consensus of $29.8 billion. The company affirmed its 2019 adjusted EPS outlook of $4.90 to $5.15, which surrounds the FactSet consensus of $4.99. The stock has rallied 9.6% over the past three months through Wednesday, while the SPDR Health Care Select Sector ETF has gained 3.4% and the S&P 500 has slipped 1.5%.
On a per-share basis, the Dublin, Ohio-based company said it had net income of $1.94. Earnings, adjusted for one-time gains and costs, were $1.29 per share. The results topped Wall Street expectations. ...
- Revenue increased 8 percent to $35.2 billion - GAAP(1) operating earnings increased 211 percent to $816 million , including a $508 million gain on sale of naviHealth; non-GAAP operating earnings decreased ...
Cardinal Health Inc. has its first independent chairman in its 47-year history, following a national trend in large public companies. Shareholders also approved nominations to a diverse nine-member board Wednesday.
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Midterm elections slated for Tuesday, the Federal Open Market Committee meets on Wednesday and Thursday, and throughout the week data is released on consumer sentiment, producer prices, and the outlook for the non-manufacturing sector.
Blue-chip stock are supposed to be a stable, solid, market-leading companies — safe investments. Blue-chip stocks are often reliable sources of income, but a dividend isn’t all that makes a blue-chip stock. No U.S. bank is bigger, or better run, than JP Morgan Chase & Co. (NYSE:JPM).
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q1; medical-gloves sub-segment likely to be soft.
The companies will host drug take-back events on National Prescription Drug Take-Back Day at more than 200 Kroger Family of Pharmacies CINCINNATI and DUBLIN, Ohio , Oct. 24, 2018 /PRNewswire/ -- The Kroger ...
The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance